XNASUPC
Market cap1mUSD
Dec 23, Last price
0.63USD
1D
-1.07%
1Q
140.17%
IPO
-84.89%
Name
Universe Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
0.04
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
2.53%
Revenues
32m
-19.52%
Net income
-6m
L-29.46%
CFO
1m
P
Profile
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | |
| Income | ||||||
Revenues | 32,309 -19.52% | 40,143 -16.34% | ||||
Cost of revenue | 35,853 | 46,732 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (3,544) | (6,589) | ||||
NOPBT Margin | ||||||
Operating Taxes | 2,313 | 752 | ||||
Tax Rate | ||||||
NOPAT | (5,858) | (7,342) | ||||
Net income | (6,163) -29.46% | (8,737) -177.18% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | 5,482 | 3,936 | ||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | 7,012 | |||||
Net debt | (13,707) | (15,627) | ||||
| Cash flow | ||||||
Cash from operating activities | 1,120 | (1,312) | ||||
CAPEX | (44) | (94) | ||||
Cash from investing activities | (44) | (3,908) | ||||
Cash from financing activities | (1,391) | 3,318 | ||||
FCF | (7,783) | 6,324 | ||||
| Balance | ||||||
Cash | 18,504 | 18,860 | ||||
Long term investments | 685 | 703 | ||||
Excess cash | 17,574 | 17,556 | ||||
Stockholders' equity | 10,254 | 17,163 | ||||
Invested Capital | 34,762 | 33,048 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 3,625 | 3,625 | ||||
Price | 0.95 68.14% | 0.57 -77.13% | ||||
Market cap | 3,444 68.14% | 2,048 -77.13% | ||||
EV | (10,263) | (13,579) | ||||
EBITDA | (3,036) | (6,055) | ||||
EV/EBITDA | 3.38 | 2.24 | ||||
Interest | 157 | 162 | ||||
Interest/NOPBT | ||||||